Semaglutide

Status:
Do Not Prescribe (DNP), Grey, Red, Green
Decision Date:
February 2019
 

Comments

Prescribe by brand.

Subcutaneous preparation:

Ozempic 

GREEN - Ozempic is the preferred weekly GLP1 for type 2 diabetes. Use in patients who require a weekly GLP1 preparation.

Use of weekly preparation include:

    1. if compliance is an issue or
    2. if the patient requires regular visits from a nursing team to administer the drug

See local type 2 guidance. Semaglutide has the added benefit of positive cardiovascular outcomes in clinical trials. (Decision date - Dec 2022)

Wegovy 

RED: NICE TA875Wegovy is the preferred brand for managing overweight and obesity in adults. (Decision date - April 2023)

DNP: NICE TA910 - Semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal). (Decision date - Aug 2023)

 

Oral preparation:

GREEN - Rybelsus once daily oral preparation for type 2 diabetes (Decision date - February 2024)  

  • GLP-1s to be used as per NICE NG28 for further intensification.
  • oral semaglutide is taken on an empty stomach and at least 30 minutes before eating or taking other medicines. 



Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app